TP53 and non-small cell lung carcinoma: The combination dose was, hence, tested for cytotoxicity in vitro on the genotype observed in two main groups of activating mutations found in NSCLC patients, the EGFR-LKB1-RAS (A549 cell line) and EGFR-LKB1-RAS-p53 (A549-R175H p53 mutant cell line), in both normoxia and hypoxia.